Daily Cardiology Research Analysis
Three randomized clinical trials in NEJM report clinically meaningful advances across heart failure and arrhythmia care: digitoxin reduced the composite of death or heart failure hospitalization in HFrEF; active potassium optimization to a high‑normal range lowered arrhythmic events, HF hospitalization, or death in ICD patients; and a multidomain rehabilitation program reduced cardiovascular death or unplanned cardiovascular hospitalization in older post‑MI patients. Together, they support pragm
Summary
Three randomized clinical trials in NEJM report clinically meaningful advances across heart failure and arrhythmia care: digitoxin reduced the composite of death or heart failure hospitalization in HFrEF; active potassium optimization to a high‑normal range lowered arrhythmic events, HF hospitalization, or death in ICD patients; and a multidomain rehabilitation program reduced cardiovascular death or unplanned cardiovascular hospitalization in older post‑MI patients. Together, they support pragmatic, implementable strategies spanning pharmacotherapy, electrolyte management, and rehabilitation.
Research Themes
- Heart failure therapeutics and decongestion strategies
- Arrhythmia risk mitigation via electrolyte optimization
- Multidomain cardiac rehabilitation in older adults post-MI
Selected Articles
1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.
In a double-blind, placebo-controlled international RCT (n=1212), digitoxin added to guideline-directed therapy in HFrEF reduced the composite of all-cause death or first HF hospitalization (HR 0.82). All-cause mortality and first HF hospitalization individually trended favorable without statistical significance; serious adverse events were infrequent.
Impact: This high-quality RCT revisits a classic agent in the modern HFrEF era and demonstrates additive clinical benefit on a hard composite endpoint, potentially informing guideline updates and treatment personalization.
Clinical Implications: Digitoxin can be considered as an add-on in symptomatic HFrEF patients already on guideline-directed therapy to reduce the risk of death or worsening-HF hospitalization, with attention to dosing and monitoring for glycoside-related adverse effects.
Key Findings
- Primary composite (all-cause death or first HF hospitalization) reduced with digitoxin vs placebo (HR 0.82; 95% CI 0.69–0.98; P=0.03).
- All-cause mortality (HR 0.86; 95% CI 0.69–1.07) and first HF hospitalization (HR 0.85; 95% CI 0.69–1.05) favored digitoxin but were not individually significant.
- Serious adverse events occurred in 4.7% with digitoxin vs 2.8% with placebo.
Methodological Strengths
- International, double-blind, placebo-controlled randomized design with guideline-therapy background
- Clinically meaningful, hard composite endpoint with adequate follow-up (median 36 months)
Limitations
- Individual components did not reach statistical significance
- Slightly higher serious adverse events with digitoxin necessitate careful monitoring
Future Directions: Define target patient subgroups (e.g., rhythm status, renal function) most likely to benefit; explore dose–response and safety optimization; assess cost-effectiveness and real-world implementation.
BACKGROUND: The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. METHODS: In this international, double-blind, placebo-controlled trial, we randomly assigned patients with chronic heart failure who had a left ventricular ejection fraction of 40% or less and a New York Heart Association (NYHA) functional class of III or IV or a left ventricular ejection fraction of 30% or less and an NYHA functional class of II in a 1:1 ratio to receive digitoxin (at a starting dose of 0.07 mg once daily) or matching placebo in addition to guideline-directed medical therapy. The primary outcome was a composite of death from any cause or hospital admission for worsening heart failure, whichever occurred first. RESULTS: Among 1240 patients who underwent randomization, 1212 fulfilled the criteria for inclusion in the modified intention-to-treat population: 613 patients in the digitoxin group and 599 in the placebo group. Over a median follow-up of 36 months, a primary-outcome event occurred in 242 patients (39.5%) in the digitoxin group and 264 (44.1%) in the placebo group (hazard ratio for death or first hospital admission for worsening heart failure, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03). Death from any cause occurred in 167 patients (27.2%) in the digitoxin group and 177 (29.5%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.69 to 1.07). A first hospital admission for worsening heart failure occurred in 172 patients (28.1%) in the digitoxin group and 182 (30.4%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.69 to 1.05). At least one serious adverse event occurred in 29 patients (4.7%) in the digitoxin group and 17 (2.8%) in the placebo group. CONCLUSIONS: Treatment with digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure than placebo among patients with heart failure and reduced ejection fraction who received guideline-directed medical therapy. (Funded by the German Federal Ministry of Research, Technology, and Space and others; DIGIT-HF EudraCT number, 2013-005326-38.).
2. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.
In a multicenter, open-label randomized trial (n=1200 ICD patients with K≤4.3 mmol/L), active potassium optimization to 4.5–5.0 mmol/L reduced the composite of sustained VT/appropriate ICD therapy, unplanned arrhythmia or HF hospitalization, or all-cause death (HR 0.76) without increasing hospitalizations for hyperkalemia or hypokalemia.
Impact: This pragmatic electrolytic strategy trial demonstrates that targeting high-normal potassium can translate into fewer arrhythmic and HF events and deaths in a high-risk ICD population, with actionable pathways (supplementation, MRA, diet) and reassuring safety.
Clinical Implications: For ICD recipients with K≤4.3 mmol/L, proactive titration to 4.5–5.0 mmol/L (using supplements and/or MRA plus dietary counseling) can be adopted to reduce arrhythmic therapies, HF admissions, and mortality, with routine monitoring to avoid dyskalemias.
Key Findings
- Primary composite endpoint reduced with potassium optimization vs standard care (HR 0.76; 95% CI 0.61–0.95; P=0.01).
- Event rates: 7.3 vs 9.6 per 100 person-years (intervention vs control).
- Hospitalizations for hyperkalemia or hypokalemia were similar between groups.
Methodological Strengths
- Event-driven randomized superiority design with sizable cohort and long follow-up
- Clear, protocolized intervention with clinically relevant composite outcome
Limitations
- Open-label design may introduce performance bias
- Single-country setting may limit generalizability
Future Directions: Assess applicability in broader populations (non-ICD high-risk cohorts), integration with RAAS inhibitor optimization, and cost-effectiveness; define optimal monitoring algorithms to maintain target potassium safely.
BACKGROUND: Hypokalemia and even low-normal plasma potassium levels increase the risk of ventricular arrhythmias among patients with cardiovascular disease. An assessment of a strategy of actively increasing plasma potassium levels to the high-normal range is needed. METHODS: In this multicenter, open-label, event-driven, randomized superiority trial conducted in Denmark, we enrolled participants at high risk for ventricular arrhythmias (defined as those with an implantable cardioverter-defibrillator [ICD]) and with a baseline plasma potassium level of 4.3 mmol per liter or lower. Participants were randomly assigned, in a 1:1 ratio, to a treatment regimen aimed at increasing the plasma potassium level to a high-normal level (4.5 to 5.0 mmol per liter) by means of potassium supplementation, a mineralocorticoid receptor antagonist, or both plus dietary guidance and standard care (high-normal potassium group) or to standard care only (standard-care group). The primary end point was a composite of documented sustained ventricular tachycardia or appropriate ICD therapy, unplanned hospitalization (>24 hours) for arrhythmia or heart failure, or death from any cause, assessed in a time-to-first-event analysis. RESULTS: Among the 1200 participants who underwent randomization (600 assigned to each group), the median duration of follow-up was 39.6 months (interquartile range, 26.4 to 49.3). A primary end-point event occurred in 136 participants (22.7%; 7.3 events per 100 person-years) in the high-normal potassium group, as compared with 175 participants (29.2%; 9.6 events per 100 person-years) in the standard-care group (hazard ratio, 0.76; 95% confidence interval, 0.61 to 0.95; P = 0.01). The incidence of hospitalization for hyperkalemia or hypokalemia was similar in the two groups. CONCLUSIONS: Among participants with any cardiovascular disease who had an ICD and were at high risk for ventricular arrhythmias, a treatment-induced increase in plasma potassium levels led to a significantly lower risk of appropriate ICD therapy, unplanned hospitalization for arrhythmia or heart failure, or death from any cause than standard care. (Funded by the Independent Research Fund Denmark and others; POTCAST ClinicalTrials.gov number, NCT03833089.).
3. Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
In older post-MI patients (median age 80) with impaired physical performance, a multidomain rehabilitation program (risk factor control, dietary counseling, and exercise) reduced the 1-year composite of CV death or unplanned CV hospitalization (HR 0.57) without serious adverse events.
Impact: Provides high-level evidence that structured, multidomain cardiac rehabilitation benefits a frail, often underrepresented population, with clear reduction in clinically relevant events.
Clinical Implications: Cardiac rehabilitation for older post-MI patients with poor physical performance should include coordinated risk factor management, nutrition counseling, and supervised exercise to reduce 1-year CV events; programs should be tailored for age-related needs and accessibility.
Key Findings
- Primary composite endpoint reduced with multidomain rehab vs usual care (12.6% vs 20.6%; HR 0.57; 95% CI 0.36–0.89; P=0.01).
- Unplanned CV hospitalization reduced (9.1% vs 17.6%; HR 0.48; 95% CI 0.29–0.79).
- No serious adverse events attributable to the intervention were reported.
Methodological Strengths
- Multicenter randomized design with clinically meaningful composite outcome
- Targeted a frail, older population often excluded from trials
Limitations
- Open-label behavioral intervention; potential performance bias
- Conducted in a single country; external validity may vary
Future Directions: Evaluate scalability via hybrid or home-based models, long-term sustainability of benefits, and cost-effectiveness; identify key components driving benefit for streamlined implementation.
BACKGROUND: The benefit of rehabilitation interventions in patients who are 65 years of age or older with myocardial infarction and impaired physical performance remains unclear. METHODS: In this multicenter, randomized trial conducted in Italy, we assigned older patients with impaired physical performance 1 month after myocardial infarction in a 2:1 ratio to receive either an intervention consisting of control of cardiovascular risk factors, dietary counseling, and exercise training (intervention group) or usual care (control group). The primary outcome was a composite of cardiovascular death or unplanned hospitalization for cardiovascular causes within 1 year. RESULTS: A total of 512 patients underwent randomization (342 to the intervention group and 170 to the control group). The median age of the patients was 80 years, and 36% were women. A primary-outcome event occurred in 43 patients (12.6%) in the intervention group and in 35 patients (20.6%) in the control group (hazard ratio, 0.57; 95% confidence interval, 0.36 to 0.89; P = 0.01). Cardiovascular death occurred in 14 patients (4.1%) in the intervention group and in 10 patients (5.9%) in the control group (hazard ratio, 0.69; 95% CI, 0.31 to 1.55). Unplanned hospitalization for cardiovascular causes occurred in 31 patients (9.1%) in the intervention group and in 30 patients (17.6%) in the control group (hazard ratio, 0.48; 95% CI, 0.29 to 0.79). There were no serious adverse events associated with the intervention. CONCLUSIONS: Among older patients with impaired physical performance 1 month after myocardial infarction, a multidomain rehabilitation intervention resulted in a lower incidence of cardiovascular death or unplanned cardiovascular hospitalization within 1 year than usual care. (Funded by the Italian Health Ministry; PIpELINe ClinicalTrials.gov number, NCT04183465.).